Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Detomidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.34 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.34 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.33 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.32 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.32 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.32 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.32 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.32 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PRKACA | P17612 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Detomidine SCHEMBL21624996 | 0.98 | SLC6A2 (0.33) | ALDH1A1SLC6A2SLC6A4SLC6A3GPR84 | |
| Detomidine SCHEMBL247340 | 0.98 | ALDH1A1 (0.35) | ALDH1A1SLC6A2SLC6A4SLC6A3GPR84 | |
| Detomidine SCHEMBL7087060 | 0.98 | ALDH1A1 (0.35) | ALDH1A1SLC6A2SLC6A4SLC6A3GPR84 | |
| Detomidine SCHEMBL20362222 | 0.97 | ALDH1A1 (0.34) | ALDH1A1SLC6A2SLC6A4SLC6A3GPR84 | |
| Detomidine SCHEMBL21618409 | 0.97 | ALDH1A1 (0.34) | ALDH1A1SLC6A2SLC6A4SLC6A3GPR84 | |
| Detomidine SCHEMBL28676651 | 0.97 | ALDH1A1 (0.34) | ALDH1A1SLC6A2SLC6A4SLC6A3GPR84 | |
| Detomidine SCHEMBL20362216 | 0.90 | ESR1 (0.33) | ALDH1A1SLC6A2SLC6A4SLC6A3ESR1 | |
| Detomidine SCHEMBL20362221 | 0.90 | ESR1 (0.33) | ALDH1A1SLC6A2SLC6A4SLC6A3ESR1 | |
| Detomidine SCHEMBL28311140 | 0.90 | KDM4C (0.36) | SLC6A2SLC6A4SLC6A3ESR1ESR2 | |
| Detomidine SCHEMBL20362224 | 0.89 | ESR1 (0.32) | ALDH1A1SLC6A2SLC6A4SLC6A3ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12239634-B2 | Methods of treating pruritus | CLEXIO BIOSCIENCES LTD. (IL) | 2025-03-04 | — | — | US | claimed |
| US-11903928-B2 | Methods of treating pruritus | CLEXIO BIOSCIENCES LTD. (IL) | 2024-02-20 | — | — | US | claimed |
| US-20240033252-A1 | Methods of Treating Pruritus | CLEXIO BIOSCIENCES LTD. (IL) | 2024-02-01 | — | — | US | claimed |
| US-20230398098-A1 | TOPICAL DETOMIDINE FORMULATIONS | CLEXIO BIOSCIENCES LTD. (IL) | 2023-12-14 | — | — | US | claimed |
| US-20230172909-A1 | TOPICAL DETOMIDINE FORMULATIONS | CLEXIO BIOSCIENCES LTD. (IL) | 2023-06-08 | — | — | US | claimed |
| US-20220054456-A1 | Methods Of Treating Pruritus | CLEXIO BIOSCIENCES LTD. (IL) | 2022-02-24 | — | — | US | claimed |
| US-11185532-B2 | Methods of treating pruritus | CLEXIO BIOSCIENCES LTD. (IL) | 2021-11-30 | — | — | US | claimed |
| US-20210323929-A1 | Purified Detomidine, Process of Preparing and Methods of Use | CLEXIO BIOSCIENCES LTD (IL) | 2021-10-21 | — | — | US | claimed |
| US-20210220336-A1 | TOPICAL DETOMIDINE FORMULATIONS | CLEXIO BIOSCIENCES LTD. (IL) | 2021-07-22 | — | — | US | claimed |
| WO-2021037755-A1 | DETOMIDINE HYDROCHLORIDE MONOHYDRATE | SACHSE ANDREAS (DE) | 2021-03-04 | — | — | WO | claimed |
| EP-3782989-A1 | DETOMIDINE HYDROCHLORIDE MONOHYDRATE | Sachse, Andreas (DE) | 2021-02-24 | — | — | EP | claimed |
| US-20200345698-A1 | Methods Of Treating Pruritus | CLEXIO BIOSCIENCES LTD. (IL) | 2020-11-05 | — | — | US | claimed |
| WO-2020222192-A1 | METHODS OF TREATING PRURITUS | CLEXIO BIOSCIENCES LTD. (IL) | 2020-11-05 | — | — | WO | claimed |
| WO-2020222188-A1 | METHODS OF TREATING PRURITUS | CLEXIO BIOSCIENCES LTD. (IL) | 2020-11-05 | — | — | WO | claimed |
| CN-107814771-A | A kind of preparation method of detomidine hydrochloride | 安徽诺全药业有限公司 | 2018-03-20 | — | — | CN | claimed |
| US-7728147-B2 | Detomidine hydrochloride crystallization method | ORION CORPORATION (FI) | 2010-06-01 | — | — | US | claimed |
| US-20080287685-A1 | Detomidine Hydrochloride Crystallization Method | ORION CORPORATION (FI) | 2008-11-20 | — | — | US | claimed |
| WO-2006108910-A1 | DETOMIDINE HYDROCHLORIDE CRYSTALLIZATION METHOD | ORION CORPORATION (FI) | 2006-10-19 | — | — | WO | claimed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-0146228-A1 | Substituted 2-mercapto-imidazoles and their preparation and use | Farmos-Yhtyma Oy (FI) | 1985-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323929-A1 | Purified Detomidine, Process of Preparing and Methods of Use | QDPR, DCTD, NEFM | SLC6A2 1829/4885SLC6A4 2489/4885SLC6A3 732/4885 |
| US-20230398098-A1 | TOPICAL DETOMIDINE FORMULATIONS | QDPR, DDT, DCTD | SLC6A2 743/4885SLC6A4 1137/4885SLC6A3 438/4885 |
| US-20210220336-A1 | TOPICAL DETOMIDINE FORMULATIONS | QDPR, DDT, DCTD | SLC6A2 743/4885SLC6A4 1137/4885SLC6A3 438/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | SLC6A2 199/4885SLC6A4 10/4885SLC6A3 72/4885 |
| US-20080287685-A1 | Detomidine Hydrochloride Crystallization Method | DDT, QDPR, NEFM | SLC6A2 1101/4885SLC6A4 2414/4885SLC6A3 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.